The Front Room — a clinical regulatory commons
RSS
GUIDANCE Final

Technical Guidelines for Evaluation of the Relevance of Adverse Events in Drug Clinical Trials

No. 31 of 2024 National Medical Products Administration
ABSTRACT — EDITORS' SUMMARY

CDE guidance on evaluating the causal relationship between adverse events and investigational drugs during clinical trials. Maps to E6(R3) §3.13 safety reporting.

TRANSLATION — NOT AN OFFICIAL DOCUMENT

Translation provided by Apprvl via DeepL for reference. Authoritative text is the Chinese-language original.

View Chinese original on NMPA ↗
EXTERNAL LINK
EXTERNAL LINK www.cde.org.cn
↗
METADATA
TypeGUIDANCE
Year2024
VersionFinal
StatusCurrent
FormatPDF
Pages17
Size~500 KB
Last reviewedJUN 2024
SOURCE
PDF · CANONICAL LINK https://www.cde.org.cn/main/news/viewInfoCommon/4a223ed70553767e810242f4510da3ac ↗
RELATED · SAME AUTHORITY
NMPA NMPA Announcement No. 125 of 2025
NMPA Announcement on Adoption of ICH E6(R3) Good Clinical Practice Guideline
NOTICE 2025
NMPA CDE, November 2025
Guiding Principles for Computerized Systems and Electronic Data in Drug Clinical Trials (Draft for Comment)
GUIDANCE 2025
NMPA 2025
Good Clinical Practice for Drugs (2025 Revision — Draft for Comments)
REGULATION 2025
NMPA 2025
Inspection Checkpoints and Judging Principles for Drug Clinical Trials
INSPECTION PROCEDURE 2025
NMPA 2024
CDE Guidance on Centralised Monitoring
GUIDANCE 2024